Fenugrec + Gymnema
Food supplement declared in France, declaration No 2022-1-242, decision dated 6 January 2022
Fenugrec + Gymnema (MGD) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- MGD
- Food business operator placing the product on the market
- MGD (FLOWER CAPS)
- Status
- Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
- Form
- Gélule
- Daily dose
- 4 gélules
- Directions for use
- 4 gélules par jour en 2 prises pendant les repas avec un verre d'eau
- Not recommended for (according to the manufacturer)
- Femmes allaitantes, Femmes enceintes, Sous antidiabétiques
- Objectives stated by the manufacturer (these are not authorised claims)
- Minceur / Glycémie
Declaration 181164, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.
Regulatory points
- Conditions légales
Trigonella foenum-graecum L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux femmes enceintes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Trigonella foenum-graecum L. | Graine | Poudre (de plantes séchées ou broyées) | 500 mg |
| Marsdenia sylvestris (Retz.) P.I.Forst. | Feuille | Extrait sec hydroalcoolique | 450 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Acide lipoïque | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| Chlorure de chrome | Chrome | pas de limite (données insuffisantes) | 25 µg |
| Oxyde de magnésium | Magnésium | 250 mg | 300 mg |
Additives
E1204, E470b
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Déconseillé aux femmes enceintes, allaitantes et chez les personnes sous traitement antidiabétique. Si besoin, demandez conseil à un professionnel de santé.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Trigonella foenum-graecum L.
Read the warning, when it applies and the studies cited
FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010; Mills et al. 2006; Hoffman 2003; Blumenthal et al. 2000).
5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Health Canada monograph dated 29 May 2026
FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Topical
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Acide lipoïque
Read the warning, when it applies and the studies cited
DL-ALPHA-LIPOIC ACID/R-ALPHA-LIPOIC ACID
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Jacob et al. 1999, Konrad et al. 1999, Packer et al. 1995).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Applies to products providing 42 milligrams or more DL-alpha-lipoic acid or 21 milligrams or more R-alpha-lipoic acid, per day.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience sweating, paleness, chills, headache, dizziness and/or confusion (as these may be symptoms of serious low blood sugar) (Bae et al., 2013; Gullo et al., 2014; Bresciani et al., 2011; Chang et al., 2009).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Fenugrec + Gymnema PHARMATECH, declared in 2022 : same declared composition
Brand : MGD
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.